Drugs / Amlexanox

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) APHTHASOL — 1996-12-17 fda.gov ↗

Trials 3

1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01975935 Jan 2014 → Apr 2016 NAFLD1, obesity disorder, type 2 diabetes mellitus University of Michigan Completed Missed primary
Phase 2 NCT01842282 Jul 2013 → Feb 2014 NAFLD1, obesity disorder, type 2 diabetes mellitus University of Michigan Terminated No outcome recorded Stop: Business
Phase 2 NCT01083875 Feb 2000 → Jun 2001 mucositis Access Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as amlexanox ClinicalTrials.gov intervention name — accepted as the source's own label NCT01083875 ↗
2

NCT01975935 ↗

NCT01842282 ↗

Known as AA-673 ChEMBL registry synonym — accepted as the source's own label CHEMBL1096 ↗
Known as Amlexanoxo ChEMBL registry synonym — accepted as the source's own label CHEMBL1096 ↗
Known as Amoxanox ChEMBL registry synonym — accepted as the source's own label CHEMBL1096 ↗
Known as Aphthasol ChEMBL registry synonym — accepted as the source's own label CHEMBL1096 ↗
Known as Aphtheal ChEMBL registry synonym — accepted as the source's own label CHEMBL1096 ↗
Known as CHX 3673 ChEMBL registry synonym — accepted as the source's own label CHEMBL1096 ↗
Known as Elics ChEMBL registry synonym — accepted as the source's own label CHEMBL1096 ↗
Known as Solfa ChEMBL registry synonym — accepted as the source's own label CHEMBL1096 ↗
Action Inhibit “the most potent and specific inhibitor discovered was amlexanox” NCT01975935 ↗
Modality Small molecule — CHEMBL1096 ↗
Route Oral “0.5% amlexanox oral rinse” NCT01083875 ↗